CNS Pharmaceuticals Inc. has announced promising scientific research results concerning their lead program, TPI 287, at the Brain Tumor Biotech Summit. TPI 287, an abeotaxane, is in development for treating glioblastoma multiforme (GBM) and has been granted Orphan Drug Designation by the FDA for treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. Unlike other taxanes that struggle to penetrate the blood-brain barrier $(BBB.UK)$, TPI 287 has shown potential in crossing the BBB to treat central nervous system tumors. In a Phase 1 trial, when used in combination with bevacizumab, TPI 287 demonstrated efficacy with 3 Complete Responses and 9 Partial Responses among 23 evaluable glioblastoma patients. These findings highlight the drug candidate's promise as a novel treatment option for brain tumors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。